FDA warns of increased bleeding risk tied to rivaroxaban

03/17/2009 | CNNMoney

An FDA review showed that anti-coagulant rivaroxaban outperformed enoxaparin in stopping blood clots but almost doubled the risk of bleeding. Johnson & Johnson, which developed rivaroxaban with Bayer, said the treatment has a "favorable safety profile" and that all anti-clotting medicines come with bleeding risk. On Thursday, a panel of FDA advisers will evaluate the drug for approval.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT